The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: A case report of severe thermal burn injury

Journal of Infection and Chemotherapy

Volumn 17, Issue 3, 2011, Pages 407-411

  Aoki, Yosuke ^a   Urakami, Toshiharu ^a   Magarifuchi, Hiroki ^a   Nagasawa, Zenzo ^a   Nagata, Masaki ^a   Fukuoka, Mami ^a  

^a SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bacteremia; Cefepime; Pharmacokinetics pharmacodynamics (PK PD); Pseudomonas aeruginosa; Thermal burn injury

Indexed keywords

C REACTIVE PROTEIN; CEFAZOLIN; CEFEPIME; CREATININE; MEROPENEM; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; BODY SURFACE; BURN; CASE REPORT; COMPARTMENT MODEL; CREATININE CLEARANCE; DEHYDRATION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INFUSION; DRUG MONITORING; ERADICATION THERAPY; FEVER; FLUID BALANCE; FLUID RESUSCITATION; FLUID SHIFT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJURY SEVERITY; LEUKOCYTOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUTRITIONAL SUPPORT; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA BACTEREMIA; SKIN CULTURE; SKIN TRANSPLANTATION; THERMAL INJURY; WOUND CLOSURE;

EID: 80051579908     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-010-0119-8     Document Type: Article

References (27)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
2. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(suppl 1):S42-50. (Pubitemid 36140468)
3. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:1111-6.
4. Mikamo H. Investigation on optimal regimen of ceftazidime against infection caused by Pseudomonas aeruginosa using Monte Carlo simulation. Jpn J Antibiot. 2007;60:387-93. (Pubitemid 351154894)
5. Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6:805-24.
6. Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA. Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob Agents Chemother. 1999;43:2848-54.
7. Sampol E, Jacquet A, Viggiano M, Bernini V, Manelli JC, Lacarello B, et al. Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother. 2000;46:315-7. (Pubitemid 30639307)
8. Conil JM, Geroges B, Lavit M, Seguin T, Samii K, et al. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther. 2007;45:529-38. (Pubitemid 47527452)
9. Bourget P, Lesne-Hullin A, Le Reveillé R, Le Bever H, Carsin H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother. 1996;40:139-45. (Pubitemid 26020754)
10. Boucher BA, Hickerson WL, Kuhl DA, Bombassaro AM, Jaresko GS. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther. 1990;48:130-7. (Pubitemid 20263241)
11. Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough D III. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother. 1991;35:57-61.
12. Agnihotri N, Gupta V, Joshi RM. Aerobic bacterial isolates from burn wound infections and their antibiograms-a five year study. Burns. 2004;30:241-3. (Pubitemid 38479902)
13. Branski LK, Al-Mousawi A, Rivero H, Jeschke MG, Sanford AP, Herndon DN. Emerging infections in burns. Surg Infect. 2009;10:389-97.
14. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. Wayne: Clinical and Laboratory Standards Institute; 2010.
15. Isla A, Arzuaga A, Maynar J, Gascón AR, Solinis MA, Corral E, et al. Determination of ceftazidime and cefepime in plasma and dialysate- ultrafiltrate from patients undergoing continuous venovenous hemodiafiltration by HPLC. J Pharm Biomed Anal. 2005;39:996-1005. (Pubitemid 41441729)
16. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183-95. (Pubitemid 8133359)
17. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990;34:1118-22. (Pubitemid 20177364)
18. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36:552-7.
19. Livornese LL, Slavin D, Benz RL, Ingerman MJ, Santoro J. Use of antibacterial agents in renal failure. Infect Dis Clin North Am. 2001;15:983-1002. (Pubitemid 32852825)
20. Andes DR, Craig WA. Cephalosporins. In: Mandell GR, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2010. p. 323-39.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Ryback M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
23. Sharma BR. Infections in patients with severe burns: causes and prevention thereof. Infect Dis Clin North Am. 2007;21:745-59. (Pubitemid 47371195)
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-929.
25. Bhat SV, Peleg AY, Lodise TP, Shutt KA, Capitano B, Potoski BA, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother. 2007;51:4390-5. (Pubitemid 350209894)
26. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration (T[MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345-51.
27. Roos JF, Bulitta J, Lipman J, Kirkpatrick CMJ. Pharmacokinetic- pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother. 2006;58:987-93.